These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12016673)

  • 21. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA notifications. FDA approves pediatric dosing for ritonavir.
    AIDS Alert; 2005 Nov; 20(11):129-30. PubMed ID: 16365934
    [No Abstract]   [Full Text] [Related]  

  • 23. Lower dose of ritonavir approved for use with fosamprenavir.
    Sax PE
    AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
    [No Abstract]   [Full Text] [Related]  

  • 24. New drugs.
    Hussar DA
    Nursing; 1996 May; 26(5):52-6. PubMed ID: 8710288
    [No Abstract]   [Full Text] [Related]  

  • 25. New drug approvals in 1996.
    Wynn RL
    Gen Dent; 1997; 45(3):224-7. PubMed ID: 9515422
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent antiviral approvals.
    AIDS Patient Care STDS; 1999 Jun; 13(6):375. PubMed ID: 10842860
    [No Abstract]   [Full Text] [Related]  

  • 27. New Norvir soft-gel capsule formulation approved by FDA.
    Gaylord G
    Posit Living; 1999 Aug; 8(7):11. PubMed ID: 12492076
    [No Abstract]   [Full Text] [Related]  

  • 28. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 31. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA notifications. FDA approves new formulation of Lexiva.
    AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial: time to end the death trials.
    James JS
    AIDS Treat News; 1996 Aug; (no 252):1-4. PubMed ID: 11363751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA new drug approvals in 2009.
    Wynn RL
    Gen Dent; 2010; 58(4):280-4. PubMed ID: 20591770
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
    [No Abstract]   [Full Text] [Related]  

  • 36. Kaletra lower-strength pediatric tablet approved in Europe.
    AIDS Patient Care STDS; 2008 May; 22(5):437-8. PubMed ID: 18521973
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 38. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
    Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
    Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric efficacy supplement for Videx EC.
    AIDS Patient Care STDS; 2008 Nov; 22(11):919. PubMed ID: 19043843
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.